Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG)

International Journal of Infectious Diseases

Volumn 14, Issue 2, 2010, Pages

  Lech Maranda, Ewa ^a   Seweryn, Marek ^b   Giebel, Sebastian ^b   Holowiecki, Jerzy ^b   Piatkowska Jakubas, Beata ^c   Wegrzyn, Joanna ^c   Skotnicki, Aleksander ^c   Kielbinski, Marek ^d   Kuliczkowski, Kazimierz ^d   Paluszewska, Monika ^e   Jedrzejczak, Wieslaw Wiktor ^e   Dutka, Magdalena ^f   Hellmann, Andrzej ^f   Flont, Marcin ^g   Zdziarska, Barbara ^g   Palynyczko, Grazyna ^h   Konopka, Lech ^h   Szpila, Tomasz ^h   Gawronski, Krzysztof ⁱ   Sulek, Kazimierz ⁱ   Sokolowski, Jaroslaw ^j   Kloczko, Janusz ^j   Warzocha, Krzysztof ^h   Robak, Tadeusz ^a   more..

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

ⁱ MILITARY INSTITUTE OF MEDICINE   (Poland)

^j Bialystok Medical Academy   (Poland)

more..

Author keywords

Acute myeloid leukemia; Chemotherapy; Cladribine; Infections; Neutropenia

Indexed keywords

CLADRIBINE; COTRIMOXAZOLE; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ASPERGILLOSIS; BACTEREMIA; BACTERIAL INFECTION; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDIASIS; CATHETER INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNGEMIA; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFECTION COMPLICATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOUTH INFECTION; MYCOSIS; OUTCOME ASSESSMENT; PYREXIA IDIOPATHICA; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; CANDIDA; CLADRIBINE; CYTARABINE; DAUNORUBICIN; FEMALE; FUNGEMIA; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76449086915     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.02.021     Document Type: Article

References (39)

1. Klastersky J., Paesmans M., Rubenstein E.B., Boyer M., Elting L., Feld R., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 (2000) 3038-3051
2. Giamarellou H., and Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am 15 (2001) 457-482
3. Del Giudice I., and Foa R. New therapies in onco-hematology and new infectious risk factors. Rev Clin Exp Hematol 9 (2005) E1
4. Ray-Coquard I., Borg C., Bachelot T., Fayette J., Zufferey L., Guastalla J.P., et al. Prognostic factors for febrile neutropenia. Bull Cancer 93 (2006) 501-506
5. Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H., et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60 (1982) 454-462
6. Wiernik P.H., Banks P.L., Case Jr. D.C., Arlin Z.A., Periman P.O., Todd M.B., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79 (1992) 313-319
7. Holowiecki J., Grosicki S., Robak T., Kyrcz-Krzemien S., Giebel S., Hellmann A., et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18 (2004) 989-997
8. Kantarjian H.M., Estey E.H., and Keating M.A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10 Suppl 1 (1996) S4-6
9. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 44 (2003) 391-409
10. Santana V.M., Mirro Jr. J., Kearns C., Schell M.J., Crom W., and Blakley R.L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10 (1992) 364-370
11. Kornblau S.M., Gandhi V., Andreeff H.M., Beran M., Kantarjian H.M., Koller C.A., et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10 (1996) 1563-1569
12. Wrzesień-Kuś A., Robak T., Wierzbowska A., Lech-Marańda E., Pluta A., Wawrzyniak E., et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 84 (2005) 557-564
13. Wrzesień-Kuś A., Robak T., Lech-Marańda E., Wierzbowska A., Dmoszyńska A., Kowal M., et al. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2- chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia-a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 71 (2003) 155-162
14. Cheson B.D. New antimetabolites in the treatment of human malignancies. Semin Oncol 19 (1992) 695-706
15. Robak T., Korycka A., Kasznicki M., Wrzesien-Kus A., and Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 5 (2005) 421-444
16. Robak T., Lech-Maranda E., Korycka A., and Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 13 (2006) 3165-3189
17. Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13 (1995) 2431-2448
18. Samonis G., and Kontoyiannis D.P. Infectious complications of purine analog therapy. Curr Opin Infect Dis 14 (2001) 409-413
19. Anaissie E.J., Kontoyiannis D.P., O'Brien S., Kantarjian H., Robertson L., Lerner S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129 (1998) 559-566
20. Morrison V.A., Rai K.R., Peterson B.L., Kolitz J.E., Elias L., Appelbaum F.R., et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 19 (2001) 3611-3621
21. Van Den Neste E., Michaux L., Layios N., Costantini S., Francart J., Lambert C., et al. High incidence of complications after 2-chloro-2′-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol 83 (2004) 356-363
22. Tam C.S., Wolf M.M., Januszewicz E.H., Grigg A.P., Prince H.M., Westerman D., et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 101 (2004) 2042-2049
23. Clavio M., Carrara P., Miglino M., Pierri I., Canepa L., Balleari E., et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81 (1996) 513-520
24. Montillo M., Mirto S., Petti M.C., Latagliata R., Magrin S., Pinto A., et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58 (1998) 105-109
25. Huhmann I.M., Watzke H.H., Geissler K., Gisslinger H., Jäger U., Knöbl P., et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73 (1996) 265-271
26. Vidarsson B., Abonour R., Williams E.C., Woodson R.D., Turman N.J., Kim K., et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 41 (2001) 321-331
27. Carella A.M., Cascavilla N., Greco M.M., Melillo L., Sajeva M.R., Ladogana S., et al. Treatment of 'poor risk' acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma 40 (2001) 295-303
28. Hughes W.T., Armstrong D., Bodey G.P., Brown A.E., Edwards J.E., Feld R., et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25 (1997) 551-573
29. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
30. Whimbey E., Kiehn T.E., Brannon P., Blevins A., and Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med 82 (1987) 723-730
31. Elting L.S., Rubenstein E.B., Rolston K.V., and Bodey G.P. Outcome of bacteremia in patients with cancer and neutropenia: observation from two decades of epidemiological and clinical trials. Clin Infect Dis 25 (1997) 247-259
32. Mermel L.A., Farr B.M., Sherertz R.J., Raad I.I., O'Grady N., Harris J.S., et al. Guidelines for management of intravascular catheter-related infection. Clin Infect Dis 32 (2001) 1249-1272
33. Madani T.A. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 28 (2000) 367-373
34. Juliusson G., Hoglund M., Karisson K., Lofgren C., Mollgard L., Paul C., et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 123 (2003) 810-818
35. Faderl S., Gandhi V., O'Brien S., Bonate P., Cortes J., Estey E., et al. Results of a phase I-II study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory acute leukemias. Blood 105 (2005) 940-947
36. Prentice H.G., Kibbler C.C., and Prentice A.G. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110 (2000) 273-284
37. Klastersky J., Ameye L., Maertens J., Georgala A., Muanza F., Aoun M., et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30 Suppl 1 (2007) S51-S59
38. Kanamaru A., and Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 39 Suppl 1 (2004) S7-10
39. Rolston K.V. Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40 Suppl 4 (2005) S246-S252